The hypogonadism treatment market is projected to grow from USD 4.2 billion in 2025 to USD 6.8 billion by 2035, at a CAGR of 5.0%. Testosterone Replacement Therapy will dominate with a 42.5% market share, while hospitals including hospital pharmacies will lead the distribution channel segment with a 48.6% share.